BTK and mantle cell lymphoma: The need for ROR1 expression monitoring may be particularly applicable to MCL, given that mutations of BTK or its down-stream target PLCγ leading to BTK inhibitor resistance are extremely rare in MCL, in contrast to SLL/CL in which the mutations are highly prevalent (14).